

# Obese Mice Fed a Diet Supplemented with Enzyme-Treated Wheat Bran Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria<sup>1–4</sup>

Dorothy A Kieffer,<sup>5,6,9</sup> Brian D Piccolo,<sup>10,11</sup> Maria L Marco,<sup>7</sup> Eun Bae Kim,<sup>7,12</sup> Michael L Goodson,<sup>8</sup> Michael J Keenan,<sup>13</sup> Tamara N Dunn,<sup>5,6,9</sup> Knud Erik Bach Knudsen,<sup>14</sup> Sean H Adams,<sup>5,6,10,11\*</sup> and Roy J Martin<sup>5,6,9\*</sup>

<sup>5</sup>Graduate Group in Nutritional Biology and <sup>6</sup>Department of Nutrition, <sup>7</sup>Food Science and Technology Department, and <sup>8</sup>Department of Microbiology, University of California, Davis, CA; <sup>9</sup>Obesity and Metabolism Research Unit, USDA–Agricultural Research Service Western Human Nutrition Research Center, Davis, CA; <sup>10</sup>Arkansas Children’s Nutrition Center and <sup>11</sup>Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; <sup>12</sup>Department of Animal Life Science, College of Animal Life Sciences, Kangwon National University, Chuncheon, Gangwon-do, Republic of Korea; <sup>13</sup>Louisiana State University AgCenter, Baton Rouge, LA; and <sup>14</sup>Department of Animal Science, Aarhus University, Aarhus, Denmark

---

## Abstract

**Background:** Enzyme-treated wheat bran (ETWB) contains a fermentable dietary fiber previously shown to decrease liver triglycerides (TGs) and modify the gut microbiome in mice. It is not clear which mechanisms explain how ETWB feeding affects hepatic metabolism, but factors (i.e., xenometabolites) associated with specific microbes may be involved.

**Objective:** The objective of this study was to characterize ETWB-driven shifts in the cecal microbiome and to identify correlates between microbial changes and diet-related differences in liver metabolism in diet-induced obese mice that typically display steatosis.

**Methods:** Five-week-old male C57BL/6J mice fed a 45%-lard-based fat diet supplemented with ETWB (20% wt:wt) or rapidly digestible starch (control) ( $n = 15/\text{group}$ ) for 10 wk were characterized by using a multi-omics approach. Multivariate statistical analysis was used to identify variables that were strong discriminators between the ETWB and control groups.

**Results:** Body weight and liver TGs were decreased by ETWB feeding (by 10% and 25%, respectively;  $P < 0.001$ ), and an index of liver reactive oxygen species was increased (by 29%;  $P < 0.01$ ). The cecal microbiome showed an increase in Bacteroidetes (by 42%;  $P < 0.05$ ) and a decrease in Firmicutes (by 16%;  $P < 0.05$ ). Metabolites that were strong discriminators between the ETWB and control groups included decreased liver antioxidants (glutathione and  $\alpha$ -tocopherol); decreased liver carbohydrate metabolites, including glucose; lower hepatic arachidonic acid; and increased liver and plasma  $\beta$ -hydroxybutyrate. Liver transcriptomics revealed key metabolic pathways affected by ETWB, especially those related to lipid metabolism and some fed- or fasting-regulated genes.

**Conclusions:** Together, these changes indicate that dietary fibers such as ETWB regulate hepatic metabolism concurrently with specific gut bacteria community shifts in C57BL/6J mice. It is proposed that these changes may elicit gut-derived signals that reach the liver via enterohepatic circulation, ultimately affecting host liver metabolism in a manner that mimics, in part, the fasting state. *J Nutr* 2016;146:2445–60.

---

**Keywords:** dietary fiber, gut microbiota, metabolomics, transcriptomics, xenobiotic

---

## Introduction

The world is facing unprecedented rates of overweight, obesity, and comorbidities such as type 2 diabetes and nonalcoholic fatty liver disease (NAFLD)<sup>15</sup> (1–4). Therefore, the need for affordable, accessible, and safe approaches to body-weight control and improved metabolic health are in high demand. Changes in dietary patterns, such as increased dietary fiber intake, have been shown to be effective in body-weight reduction and improved

metabolic function, at least in some contexts (5–8). Despite the proposed benefits of increased dietary fiber intake, most adults consume less than half the recommended amount (9) and the 2010 Dietary Guidelines for Americans named dietary fiber as a nutrient of concern (10). One way in which dietary fibers improve metabolic health is by altering the gut microbiota (11, 12). The human gut microbiota is characterized by trillions of microbes that possess far more protein-coding genes than the

human genome (13, 14). Unlike the human genome, which is largely fixed, the gut microbiome is plastic and can be greatly altered depending on the type of diet the host is consuming (15). There is mounting evidence that the gut microbiota participate in extensive cross-talk with the host via production of xenometabolites (e.g., SCFAs, modified amino acids, and other factors) as well as influence host gene expression (16). Importantly, the production of xenometabolites is highly influenced by host diet (17, 18). It is likely that specific xenometabolites and other microbe-derived factors serve as signals to host tissues, including the liver.

Several studies have shown that shifts in the gut microbiota can result in differences in circulating blood metabolites and alterations in liver metabolism (19, 20). Because the liver is in close proximity to the gut, receives portal blood rich in gut-derived xenometabolites and other factors, and plays a major role in regulating metabolism, an understanding of how changes in the gut microbiota affect liver physiology and biochemistry is of great interest. Therefore, we set out to characterize how the consumption of the dietary fiber enzyme-treated wheat bran (ETWB) alters the gut microbiota and liver metabolome. ETWB is made by treating wheat bran with heat and enzymes, resulting in a mixture of arabinoxylan oligosaccharides (AXOSs), high-molecular weight arabinoxylans, cellulose, and lignin (21). The treated wheat bran is more prone to bacterial degradation than is wheat bran in its native form (18, 19). Human and animal studies have shown that the consumption of ETWB can alter the gut microbiota, reduce body fat, and improve glucose and insulin homeostasis (21). However, there is a paucity of information with regard to what effects ETWB has on the liver, a major organ in terms of whole-body metabolic homeostasis. Therefore, in addition to testing the whole-body effects of ETWB on typically measured metabolic outcomes in a diet-induced obesity (DIO) mouse model, a first-ever, to our knowledge, comprehensive landscape of liver metabolism in response to ETWB was characterized through the application of transcriptomics and metabolomics tools. We hypothesized that improvements in whole-body metabolic health indexes would be associated with alterations in pathways related to liver lipid metabolism (i.e., reduced steatosis) and glucose homeostasis. Correlation

and multivariate statistical analyses were used to identify candidate microbes and metabolites that drive ETWB-associated differences in liver metabolism.

## Methods

**DIO mice and diets.** Four-week-old male C57BL/6J mice (Jackson Laboratory) were individually housed under standard temperature (20–22°C) and light-dark cycle (12 h:12 h) conditions in a specific pathogen-free facility. Mice were fed Teklad Rodent Diet 2918 (Envigo) with an energy content of 24%, 58%, and 18% of protein, carbohydrate, and fat, respectively, for a 1-wk acclimation period, then randomly assigned ( $n = 15/\text{group}$ ) to purified experimental diets containing 45% kcal from fat (Teklad; TD.08511) (22) and supplemented with rapidly digestible corn starch (control) or ETWB for 10 wk (Supplemental Table 1). The wheat bran was treated with xylanases and cellulases to increase the content of AXOSs (DuPont Industrial Biosciences Danisco A/S). Thus, the ETWB contained a mix of AXOSs and high-molecular-weight dietary fiber polysaccharides predominantly as arabinoxylan and cellulose. Mice were given ad libitum access to food and water. Body weight and food intake were recorded every 2–3 d. All animal protocols were approved by the University of California at Davis (UC Davis) Institutional Animal Care and Use Committee according to Animal Welfare Act guidelines.

**Oral-glucose-tolerance test.** At study week 8 an oral-glucose-tolerance test was performed on a subset of randomly selected mice ( $n = 10/\text{group}$ ). After 14 h of overnight food deprivation mice were orally administered a sterile solution of 25% glucose in water (1 g glucose/kg body weight). Blood glucose was measured by using a OneTouch Ultra 2 Blood Glucose Meter (LifeScan) at 0 (baseline), 15, 30, 60, and 120 min after gavage.

**Tissue harvest.** At week 10, mice were briefly feed-deprived (between 4 and 8 h, starting at 0400) before being anesthetized via isoflurane inhalation (3% in oxygen), and blood was collected by cardiac exsanguination by using EDTA-treated syringes. Mice did not survive this procedure. Blood was centrifuged at  $10,000 \times g$  for 2 min at room temperature. Plasma was collected and flash-frozen in liquid nitrogen. Epididymal fat pads, retroperitoneal fat pads, femoral subcutaneous fat pads, liver, and cecum were excised, weighed, and flash-frozen in liquid nitrogen. All tissues were stored at  $-70^\circ\text{C}$ . Total fat pad weights were used as an index of adiposity.

**Plasma assays.** Plasma glucose was assessed by using the Glucose Enzymatic Assay Kit (Sigma). Insulin was assessed by using the low-range Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chemistry). Nonesterified FAs (NEFAs) were assessed with the use of the NEFA-HR (2) microtiter procedure (Wako Diagnostics). TGs were assessed by using the L-type M Triglyceride Microtiter procedure (Wako Diagnostics). All assays were performed according to manufacturers' instructions.

**Liver TGs.** Liver lipid extraction was performed by using a modified Folch method (23). Briefly, liver tissue ( $\sim 100$  mg) was homogenized in 1 mL of a 2:1 (vol:vol) chloroform:methanol solution. The organic phase was evaporated by using a GeneVac EZ-2, then reconstituted in 1 mL isopropanol. TG content of lipid extracts was measured by using an enzymatic assay kit (TR0100; Sigma) according to manufacturer's instructions.

**Reactive oxygen species.** Reactive oxygen species (ROS) formation was estimated as described in previous reports (24). Briefly, frozen liver tissue ( $\sim 50$  mg) was sonicated for 20 s in ice-cold PBS. Aliquots of 0.5 mL were incubated with 0.5 mL of  $5\text{-}\mu\text{M}$  2',7'-dichlorofluorescein-diacetate at  $37^\circ\text{C}$  for 60 min. Dichlorofluorescein fluorescence, the fluorescent product of dichlorofluorescein diacetate, was recorded at the end of the incubation period at an excitation wavelength of 488 nm and an emission wavelength of 525 nm in a Perkin-Elmer LS55 luminescence spectrometer. A standard curve was constructed by using increasing concentrations of dichlorofluorescein. Results were expressed as nanomoles of dichlorofluorescein

<sup>1</sup> Supported in part by a T32 training award (to DAK) funded by the National Center for Advancing Translational Sciences, NIH, through grant UL1 TR000002 and linked award TL1 TR000133. Additional funding was provided by the Danish Council for Strategic Research Project 10-093526, USDA–Agricultural Research Service projects 2032-51530-022-00D and 6026-51000-010-05S, and in part by the Arkansas Biosciences Institute, the major research component of the Tobacco Settlement Proceeds Act of 2000. The University of California–Davis West Coast Metabolomics Center is funded by NIH/National Institute of Diabetes and Digestive and Kidney Diseases grant U24DK097154.

<sup>2</sup> Author disclosures: DA Kieffer, BD Piccolo, ML Marco, EB Kim, ML Goodson, MJ Keenan, TN Dunn, KEB Knudsen, SH Adams, and RJ Martin, no conflicts of interest.

<sup>3</sup> Reference to a company or product name does not imply approval or recommendation of the product to the exclusion of equivalent materials. The USDA is an equal opportunity provider and employer.

<sup>4</sup> Supplemental Tables 1–6 and Supplemental Figures 1 and 2 are available from the “Online Supporting Material” link in the online posting of the article and from the same link in the online table of contents at <http://jn.nutrition.org>.

\*To whom correspondence should be addressed. E-mail: [rmartin@agcenter.lsu.edu](mailto:rmartin@agcenter.lsu.edu) (RJ Martin), [shadams@uams.edu](mailto:shadams@uams.edu) (SH Adams).

<sup>15</sup> Abbreviations used: AXOS, arabinoxylan oligosaccharide; DIO, diet-induced obesity; ETWB, enzyme-treated wheat bran; *Fasn*, fatty acid synthase; FDR, false discovery rate; NAFLD, nonalcoholic liver disease; NEFA, nonesterified fatty acid; OTU, operational taxonomic unit; *Pck1*, phosphoenolpyruvate carboxykinase 1; PLS-DA, partial least-squares-discriminant analysis; ROS, reactive oxygen species; RNAseq, RNA sequencing; rRNA, ribosomal RNA; UC Davis, University of California at Davis; VIP, variable importance in projection.

formed per milligram of protein per minute. Protein concentrations were measured according to the method described by Lowry et al. (25).

**Cecal pH and SCFAs.** Contents were removed from the cecum and flash-frozen in liquid nitrogen and stored at  $-70^{\circ}\text{C}$ . Cecal contents were thawed on ice and homogenized in distilled water (0.5 g wet sample to 5 mL water). A combination electrode was used to measure pH. Samples were then acidified with 200  $\mu\text{L}$  of a 25% (wt:wt) solution of metaphosphoric acid that contained 2 g 2-ethyl-butyric acid/L that served as an internal standard for SCFA content. Solids in the homogenized samples were separated by centrifugation at 8000 g for 10 min. Samples were filtered through a Millipore filter (MILX HA 33 mm, 0.45- $\mu\text{m}$  MCE STRL; Fisher SLHA 033SS). SCFAs in the effluent were analyzed by GLC, similar to Barry et al. (26). Briefly, the column used was an Alltech Econo-cap EC-1000, 100% polyethylene glycol acid modified with dimensions of 15 m  $\times$  0.53 mm with a film thickness of 1.20  $\mu\text{m}$ . Settings for temperature control were as follows:  $115^{\circ}\text{C}$  for 0.1 min, temperature was increased at a rate of  $10^{\circ}\text{C}/\text{min}$  up to  $150^{\circ}\text{C}$  and held for 0.1 min, then this temperature was increased at  $11^{\circ}\text{C}/\text{min}$  up to  $170^{\circ}\text{C}$  and held for 2 min. The injector temperature was  $250^{\circ}\text{C}$ .

**Cecal microbiota.** Total cecal DNA was extracted by mechanical (0.1 mm zirconia/silica beads; BioSpec) and enzymatic lysis (lysozyme; Fischer) followed by DNA purification with the use of the QIAamp DNA stool mini kit (Qiagen). Five nanograms of DNA was used to amplify the V4 region of the 16S ribosomal RNA (rRNA) gene with 32 PCR cycles at  $94^{\circ}\text{C}$  for 45 s,  $50^{\circ}\text{C}$  for 60 s, and  $72^{\circ}\text{C}$  for 90 s by using barcoded forward 515 (GTGCCAGCMGCCGCGGTAA) and reverse 806 (GGACTACHVGGGTWTCTAAT) (27, 28). Sequencing of pooled 250-bp paired-end amplicons was performed by using Illumina MiSeq at the UC Davis Genome Center. Raw Illumina FASTQ files were demultiplexed and quality-filtered with QIIME (Quantitative Insights into Microbial Ecology) software [version 1.6.0; split\_libraries\_fastq.py, parameter settings:  $-r$  3  $-p$  0.75  $-q$  3  $-n$  0 (29)]. High-quality paired reads were assembled to obtain a single sequence with the use of a short-read assembler, FLASH (30). Assembled reads were used for operational taxonomic unit (OTU) picking. OTUs sharing  $\geq 97\%$  nucleotide identity were identified by using a closed-reference OTU picking process according to a 16S rRNA sequence database [Greengenes version 12\_10 (31)] and further analyzed in QIIME.

**Metabolomics.** The details of sample handling, metabolite detection, and analysis have been previously described (32). Briefly, untargeted metabolomics was performed at the UC Davis West Coast Metabolomics Center on plasma and liver samples by using GC-time-of-flight-MS to detect primary metabolites (i.e., purines, amino acids, sugars, etc.). For plasma, 15  $\mu\text{L}$  was added to 1 mL ice-chilled extraction solution (acetonitrile:isopropanol:water, 3:3:2) and mixed on a vortex for 10 s. This same procedure was conducted by using an  $\sim 4$  mg sample of frozen liver tissue. Samples were centrifuged for 2 min at  $14,000 \times g$  (Eppendorf 5415D), and 500  $\mu\text{L}$  supernatant was evaporated (Labconco Centrivap) to complete dryness. For derivitization, 10  $\mu\text{L}$  methoxyamine hydrochloride (Aldrich) was added to dried samples and left on a shaker for 90 min at  $30^{\circ}\text{C}$ , and then 91  $\mu\text{L}$  of 100:1 N-methyl-N-(trimethylsilyl)-trifluoroacetamide (Aldrich):FA methyl ester mixture was added. Samples were left on the shaker for 30 min at  $37^{\circ}\text{C}$ . Samples (0.5  $\mu\text{L}$ ) were separated by using an Agilent 6890 gas chromatograph equipped with a 30 m  $\times$  0.25 mm i.d., Rtx5Sil-MS column with 0.25  $\mu\text{m}$  5% diphenyl film and a 10-m integrated guard column (Restek). Chromatography was performed with a constant flow of 1 mL/min while increasing the oven temperature from  $50^{\circ}\text{C}$  to  $330^{\circ}\text{C}$  over a 22-min total run time. Mass spectra were acquired on a Leco Pegasus IV time-of-flight mass spectrometer with a  $280^{\circ}\text{C}$  transfer line, a  $250^{\circ}\text{C}$  ion source, and  $-70$  eV electron ionization impact. The acquisition rate was 17 spectra  $\text{s}^{-1}$  with a scan mass range of 85–500 Da. Result files were exported to servers and processed by the Fiehn laboratory's metabolomics database, known as BinBase (33). Database entries in BinBase were matched against the Fiehn mass spectral library of 1200 authentic metabolite spectra by using retention index and mass spectrum information or the National Institute of Standards and Technology commercial library.

Identified metabolites were reported if present in  $\geq 50\%$  of the samples (as defined in the SetupX database) (34). Each metabolite was normalized by the sum of identified metabolite quantifier ion peak heights present in each individual sample. These relative abundances were used for subsequent statistical analysis.

**RNA sequencing (RNAseq).** Total RNA was extracted from  $\sim 30$  mg liver tissue (subset of  $n = 13/\text{group}$  randomly selected from  $n = 15/\text{group}$  for RNAseq and qPCR validation) by using the Qiagen RNeasy Mini RNA Purification Kit according to the manufacturer's instructions (Qiagen). RNA abundance was quantified by using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). mRNA was isolated by using the NEBNext Poly(A) Magnetic Isolation Module (New England BioLabs). First- and second-strand synthesis was performed with the use of the NEBNext Ultra Directional RNA Library Prep Kit. Adaptor ligation for Illumina was performed by using the NEBNext Multiplex Oligos for Illumina. Purification of cDNA, ligation, and PCR reactions was performed by using AMPure XP beads (Agencourt BioSciences). RNA and DNA library quality was assessed by using the Caliper GX at the UC Davis Genome Center. Library sequencing was performed on an Illumina HiSeq 2500 at University of California, Berkeley. Library quality was assessed by using the FastQC algorithm (version 0.11.3). Sequences were aligned to the mouse genome (GRC38/m10) by using Tophat (version 2.0.14) and the Bowtie 2 aligner (version 2.2.5). Differential gene expression was determined with the use of the Cuffdiff algorithm that is part of the Cufflinks analysis suite (version 2.2.1). Pathway analysis was performed by using WebGestalt (35, 36). Genes were selected for pathway analysis input if the gene had a CuffDiff unadjusted  $P$  value  $\leq 0.05$  and both treatment groups had a mean of  $\geq 1$  fragment per kilobase of transcript per million. Analysis parameters were as follows: Organism: *Mus musculus*, Id Type: gene\_symbol, Reference Set: *mmusculus\_genome*, Statistic: Hypergeometric, Significance Level: Top10, Multiple Test Correction: Benjamini-Hochberg, Minimum number of genes for a category: 2.

**Validation qPCR.** RNA was isolated as described in the section above. Methods used were similar to that previously described (22). Briefly, the Superscript III First-Strand Synthesis System (Invitrogen) was used to synthesize cDNA from total RNA according to the manufacturer's instructions. Taqman primers and 6-carboxyfluorescein-minor groove binder labeled probes (Supplemental Table 2) were assayed in triplicate for each sample on a ViiA7 instrument (Applied Biosystems). Reactions were carried out in a 384-well format. Each well contained the following: 8 ng air-dried cDNA, 1 $\times$  Master Mix (ABI Universal Master Mix), and 1 $\times$  specific primer-probe mix. Cycle conditions were  $50^{\circ}\text{C}$  for 2 min,  $95^{\circ}\text{C}$  for 10 min, and 40 cycles of  $95^{\circ}\text{C}$  for 15 s or  $60^{\circ}\text{C}$  for 1 min. Relative gene expression was determined by using the  $\Delta\text{-}\Delta\text{Ct}$  method as previously described (37). Eukaryotic 18S rRNA (Life Technologies) was used as the endogenous reference gene. A comparison of gene expression determined by RNAseq and qPCR can be found in Supplemental Figure 1.


**Statistical analysis.** Statistical analyses were performed by using GraphPad Prism (version 5.04 for Windows) and the open-source statistical software R (version 3.1.2) (38). The significance of microbial percentage abundance and metabolomics data was assessed by using the Mann-Whitney  $U$  test, and Benjamini-Hochberg false discovery rate (FDR)-corrected  $P$  values  $\leq 0.05$  were considered significant (39). Multivariate analyses of metabolomics data were performed by using partial least-squares-discriminate analysis (PLS-DA) from the R package "pls" (40). Metabolomics data were log-transformed, and each metabolite was assessed for univariate outliers by using Grubb's test with the R package "outliers" (41). Outliers were removed if determined to be significant at  $\alpha = 0.01$ . In total, 157 outliers were removed, which accounted for only 0.6% of the entire metabolomics data. Removed outliers were imputed by using  $k$ -nearest neighbors from the Bioconductor "impute" package (42). PLS-DA model accuracy was assessed with a cross-validation scheme in which the data were randomly partitioned into training and test data sets encompassing two-thirds and one-third of mice, respectively. Model fitting and feature selection were determined solely with data from the training set. Training data were

scaled and centered to unit variance before model development, whereas test data were scaled and centered by using the means and SDs from the training data. Metabolites of interest were assessed in PLS-DA models with variable importance in projection (VIP) scores, a weighted measure of the contribution of each metabolite to discriminate the classification groups. A VIP score  $\geq 1$  has been argued to be an adequate threshold to determine discriminant variables in PLS-DA models (43, 44). Furthermore, we used bootstrapping (45) to determine a distribution of VIP scores, and then tested whether the bootstrapped VIP distribution was significantly  $\geq 1$  by using an independent 1-tailed *t* test. Metabolites meeting these criteria were chosen for inclusion in final PLS-DA model development. Model performance was assessed on the basis of the model's ability to accurately predict the classification of the test set mice (e.g., control compared with ETWB) by using data from the test set. Final models that used 2 components were able to predict the classification of test mice with 70% accuracy on the basis of plasma metabolites and 80% accuracy on the basis of liver metabolites. Principal components analysis score plots of plasma and liver metabolites can be found in **Supplemental Figure 2**. Principal components analysis is unsupervised modeling (i.e., model is not provided with treatment group assignments), whereas PLS-DA is supervised modeling (i.e., model is provided with treatment group assignments). Spearman's correlation matrices feature the following data: adiposity, cecal weight, liver TGs, and liver ROS identified by Student's *t* test as significant at  $P \leq 0.05$ ; hepatic genes identified as significantly different from CuffDiff analysis after FDR correction and named by WebGestalt pathway analysis; plasma and liver metabolites; and cecal microbes.

## Results

### Adiposity and liver TGs

Mice supplemented with ETWB showed significantly reduced body weight, adiposity index (summed fat pad weights), and feed efficiency compared with control mice (**Figure 1A**, **Table 1**).



**FIGURE 1** Body weight (A) and cumulative energy intake (B) in male mice ( $n = 15$ /group) fed a 45%-fat diet with or without a 20% (by wt) ETWB supplement for 10 wk. To convert kcal to kJ, multiply by 4.184. ETWB, enzyme-treated wheat bran.

There was a significant diet  $\times$  time interaction on cumulative energy intake ( $P < 0.0002$ ), with mean cumulative energy intake reduced in the ETWB-fed mice compared with control mice starting at day 60 of the  $\sim 70$ -d feeding intervention ( $P < 0.05$ ) (**Figure 1B**). There was no difference in AUCs with an oral-glucose-tolerance test ( $15,701 \pm 1206$  and  $15,601 \pm 694$  mg/dL  $\times$  min for control and ETWB mice, respectively) performed at week 8 of the study and no difference in terminal postabsorptive plasma glucose, insulin, TGs, or NEFAs (**Table 1**). Liver TGs were significantly reduced and liver ROS were significantly increased in ETWB mice (**Table 1**). No significant correlations between energy intake and adiposity index or energy intake and liver TGs in the control or ETWB groups were observed, but interestingly, the ETWB group maintained lower adiposity and liver TGs at any given cumulative energy intake (**Figure 2A, B**), consistent with reduced feed efficiency.

### ETWB supplementation significantly alters gut environment

Cecal tissue, cecal contents, and 48-h fecal output were significantly increased in ETWB mice compared with the control group (**Table 2**). No differences in cecal pH or cecal SCFAs (acetic, propionic, butyric, isobutyric, valeric, isovaleric, and isocaproic acids) were observed. Despite no difference in the number of cecal bacteria taxa present between groups (data not shown), there were significant shifts in cecal bacteria at both the phylum and lower taxonomic levels (**Figure 3**, **Table 3**). Compared with control mice, the ETWB mice had significantly greater proportions of Bacteroidetes and Tenericutes and significantly lower proportions of Firmicutes, Proteobacteria, and Verrucomicrobia and no difference in Actinobacteria. The bacteria described below were the main contributors to differences at the phylum level and survived FDR correction. The families *S24-7* and *Rikenellaceae* contributed to the greater percentage abundances in the Bacteroidetes phylum in the ETWB group. The order *RF39* accounted for the higher proportions of Tenericutes in the ETWB-fed mice. Firmicutes from the genus *Turicibacter* and the class *Clostridia* were reduced in the cecum of the ETWB mice. The family *Enterobacteraceae* accounted for the reduced percentage abundance in the phylum Proteobacteria in the ETWB mice. Proportions of the phylum Verrucomicrobia were reduced in the ETWB mice due to reductions in the genus *Akkermansia*.

### Plasma and liver metabolome

**Plasma.** A total of 386 plasma metabolites were detected by using the GC-time-of-flight-MS analytical platform. Of these, 133 metabolites were annotated in the metabolite database; the remaining metabolites were nonannotated and labeled with a numerical BinBase ID (**Supplemental Table 3**). A total of 78 metabolites had a mean bootstrapped VIP distribution of  $\geq 1$  in the PLS-DA model and thus contributed to discrimination of the diet groups; of these, 34 metabolites were annotated (**Figure 4A**, **Table 4**; for brevity only annotated metabolites are shown). The plasma metabolite with the highest VIP, 2-deoxyerythritol, also had the greatest percentage difference of all carbohydrate metabolites in plasma. In addition, the sugar alcohols ribitol and xylitol were higher in ETWB-fed mouse plasma, whereas 1,5-anhydroglucitol was reduced in the ETWB group. The plasma lipid metabolite with the greatest percentage difference was  $\beta$ -sitosterol in the ETWB-fed mice. Other plasma lipids and lipid derivatives that were higher in the ETWB group include pelargonic acid (C9); capric acid (C10); 1-monostearin, linoleic acid (C18:2n-6); and the ketone body  $\beta$ -hydroxybutyrate

**TABLE 1** Body weight, energy efficiency, and plasma and liver characteristics of male mice fed a 45%-fat diet with or without an ETWB supplement for 10 wk<sup>1</sup>

Variable	Control	ETWB	P <sup>2</sup>
Terminal body weight, g	34.5 ± 0.69	31.1 ± 0.39	0.0003
Adiposity index <sup>3</sup>	3.15 ± 0.17	2.37 ± 0.11	0.0007
Cumulative energy intake, <sup>4</sup> kcal/10 wk	743 ± 14	687 ± 12	0.0044
Cumulative energy intake, kcal/g terminal body weight	21.9 ± 0.4	22.5 ± 0.5	0.32
Feed efficiency, <sup>4</sup> mg body weight gained/total kcal consumed	22.7 ± 0.7	20.1 ± 0.7	0.0133
Plasma glucose, mg/dL	138 ± 4.9	154 ± 10	0.09
Plasma insulin, ng/mL	0.60 ± 0.06	0.62 ± 0.06	0.79
Plasma NEFAs, mM	0.24 ± 0.01	0.24 ± 0.01	0.65
Plasma TGs, mg/dL	52.6 ± 2.5	46.5 ± 3.6	0.18
Liver weight, g	1.19 ± 0.03	1.18 ± 0.01	0.74
Liver, % of body weight	3.44 ± 0.06	3.80 ± 0.06	0.0003
Liver TGs, mg/g	46.7 ± 3.0	35.0 ± 1.1	0.0009
Liver ROS, mmol DCF · mg protein <sup>-1</sup> · min <sup>-1</sup>	3.44 ± 0.21	4.58 ± 0.29	0.0035

<sup>1</sup> Values are means ± SEMs, *n* = 15/group. DCF, dichlorofluorescein; ETWB, enzyme-treated wheat bran; NEFA, nonesterified fatty acid; ROS, reactive oxygen species.

<sup>2</sup> Derived by using 2-tailed Student's *t* test. *P* < 0.05 was considered significant.

<sup>3</sup> Adiposity index is the sum of epididymal, retroperitoneal, and subcutaneous fat pads in grams. Samples were collected from mice in the postabsorptive state after ~4–8 h food deprivation in the morning.

<sup>4</sup> To convert kcal to kJ, multiply by 4.184.


(3-hydroxybutanoic acid). Adenosine-5-phosphate had the greatest percentage difference of any nitrogenous metabolite in the plasma in the ETWB-fed mice compared with controls. Several other nitrogenous metabolites were reduced in the ETWB mouse plasma including the following: 2-hydroxyglutaric acid, 5-methoxytryptamine, creatinine, and taurine. Other metabolite differences in the ETWB-fed mice included higher abundances of hydrocinnamic acid (3-phenylpropanoic acid) and 2-ketoisocaproic acid as well as differences in the organic acids lactic acid and pyruvic acid.

**Liver.** A total of 454 liver metabolites were detected, 162 of which were annotated (Supplemental Table 4). The abundances of 110 metabolites were identified by PLS-DA to significantly contribute to separation between treatment groups; 49 of these metabolites were annotated (Figure 4B, Table 5; for brevity only annotated metabolites are shown). As in plasma, several sugars and sugar alcohols were reduced in the livers of ETWB-fed mice including the following: glucose, maltose, 1,5-anhydroglucitol, ribitol, and xylitol. Many lipid liver metabolites were also reduced in the ETWB group, including 1-monostearin, arachidonic acid, isoheptadecanoic acid, myristic acid (C14), oleic acid, and palmitic acid. Just as in plasma, the liver abundance of the ketone body β-hydroxybutyrate was higher in ETWB-fed mice. The following amino acids were reduced in the ETWB group: alanine, asparagine, leucine, methionine, phenylalanine, proline, threonine, tryptophan, and tyrosine. Aspartic acid was higher in the ETWB group. The following purine- and pyrimidine-related metabolites were reduced in the ETWB group: cytidine-5'-diphosphate, uridine, allantoic acid, inosine, inosine-5'-monophosphate, xanthine, and hypoxanthine. The antioxidants α-tocopherol and glutathione were reduced in ETWB livers.

### Alterations in hepatic metabolic gene expression

A transcriptomics study was conducted to determine if gene expression patterns associated with specific biochemical pathways might explain ETWB-related metabolite shifts observed in the liver. Fifty-eight protein-coding genes in the liver were considered significantly differentially expressed between treatment

groups after FDR correction and an additional 392 genes had an unadjusted *P* value ≤ 0.05 (Supplemental Table 5). Pathway analysis of genes that maintained significance after FDR



**FIGURE 2** Correlations between cumulative energy intake and total white adipose tissue weight (A) and liver TG concentrations (B) in male mice (*n* = 15/group) fed a 45%-fat diet with or without an ETWB supplement (20% by wt) for 10 wk. To convert kcal to kJ, multiply by 4.184. ETWB, enzyme-treated wheat bran.

**TABLE 2** Fecal and cecal characteristics of male mice fed a 45%-fat diet with or without an ETWB supplement for 10 wk<sup>1</sup>

Variable	Control	ETWB	P <sup>2</sup>
Fecal output, <sup>3</sup> mg/48 h	517 ± 23	688 ± 14	<0.0001
Cecal tissue, <sup>4</sup> mg	54.4 ± 2.3	76.4 ± 3.3	<0.0001
Cecal contents, mg	177 ± 6	247 ± 10	<0.0001
Cecal pH	7.9 ± 0.1	7.8 ± 0.1	0.24
Total cecal SCFAs, <sup>5</sup> μmol	6.2 ± 1.2	5.1 ± 0.7	0.44

<sup>1</sup> Values are means ± SEMs, *n* = 15/group unless otherwise noted. ETWB, enzyme-treated wheat bran.

<sup>2</sup> Derived by using 2-tailed Student's *t* test. *P* ≤ 0.05 was considered significant.

<sup>3</sup> *n* = 10/group.

<sup>4</sup> Contents removed from the cecum and tissue weight were recorded.

<sup>5</sup> Total SCFAs quantified by summing concentrations (mmol/g) of acetic, propionic, butyric, isobutyric, valeric, isovaleric, and isocaproic acids

correction revealed that 10 Kyoto Encyclopedia of Genes and Genomes pathways were affected by ETWB treatment (Table 6). Genes involved in lipid metabolism were generally increased in the following pathways: arachidonic acid metabolism, biosynthesis of unsaturated FAs, and retinol metabolism. Insulin signaling and cell cycle pathways were also affected by ETWB feeding. Pathway analysis was also conducted including genes with unadjusted *P* values ≤ 0.05, which is shown in Supplemental Table 6. Eight genes were validated by qPCR (Supplemental Figure 1). Cross-correlation plots of hepatic gene transcripts identified as significantly different from CuffDiff analysis after FDR correction and named by WebGestalt pathway analysis and PLS-DA selected plasma and liver metabolites are shown in Figures 5 and 6, respectively.

#### Potential connections between specific cecal bacteria and host metabolic health indexes, hepatic gene expression, and plasma and liver metabolites


A goal of this experiment was to identify candidate gut bacteria subpopulations that drive whole-body and liver metabolic phenotypes. A cross-correlation plot revealed significant correlations among specific cecal bacteria and adiposity, cecal weight, liver TGs, and liver ROS as well as hepatic gene transcripts (Figure 7). Five bacterial taxonomic groups (Bacteroidetes families *S24-7* and *Rikellenaceae* and the following Firmicutes: order *RF39*, family *Ruminococcaceae*, and genus *Adlercreutzia*) had negative correlations with adiposity index and liver TGs and a positive correlation with cecal weight. These same 5 taxa had significantly greater percentage abundances in the ETWB mice. Conversely, 4 bacterial taxa had the opposite relation (Firmicutes genera *Streptococcus*, *Turicibacter*, the class *Clostridia*, and the genus *Akkermansia* from the phylum Verrucomicrobia); these taxa were significantly reduced in the ETWB mice. Furthermore, these same 4 taxa had negative correlations with liver cytochrome P450 gene transcripts. To further consider potential contributions of gut bacterial shifts to modifying the host metabolome, we performed correlations among cecal bacteria compared with PLS-DA-selected plasma and liver metabolites, which are presented in Figures 5 and 6, respectively.

## Discussion

This study provides, for the first time to our knowledge, a comprehensive picture of the changes in hepatic metabolic and molecular physiology outcomes associated with microbiota shifts in response to a diet rich in fiber; in this case, ETWB. These

observations provide candidate pathways that may be relevant to the mechanisms underlying the effects of dietary fiber on whole-body metabolism. Animal models and humans supplemented with AXOSs, the primary component of ETWB, at amounts between 5% and 10% (wt:wt) of rodent diets or 6–15 g/d in humans, exhibited a broad range of health improvements including the following: decreased body weight and liver TGs, increased gut satiety hormones, improved glucose homeostasis and immunomodulatory activities, and increased abundances of putatively beneficial gut bacteria (46–50). Consistent with this, mice supplemented with ETWB in the current study gained less weight over time and had decreased liver TGs. These decreases may partially be accounted for by decreased energy intake and/or energy utilization; however, there are additional mechanisms involved because there was little to no correlation between cumulative energy intake and adiposity index or liver TGs. Future studies are warranted to test the impact of ETWB on energetics and energy balance in the context of equivalent body weight.

One possibility is that ETWB leads to increased fecal energy loss (51). Fecal energy was not measured, because the intent of this study was to identify shifts in liver metabolism and cecal bacteria induced by ETWB feeding; however, fecal output was significantly increased in the ETWB-fed mice consistent with higher energy loss via this route. Nevertheless, mice remained in positive energy balance and gained weight during the study. The reduced concentrations of liver TGs observed in the ETWB-fed mice concurrent with increased liver ROS [which increase with enhanced fat oxidation (52)] may indicate increased hepatic mitochondrial β-oxidation. This idea is supported by significantly increased plasma and liver concentrations of the ketone body β-hydroxybutyrate in the ETWB group. Reduced concentrations of the antioxidants α-tocopherol and glutathione in the liver of ETWB-fed mice may be due to increased hepatic ROS concentrations. Overall, these differences suggest that ETWB



**FIGURE 3** Unweighted UniFrac Beta-Diversity Principal Coordinates Analysis plot shows the separation between treatment groups on the basis of the cecal microbiota of male mice (*n* = 15/group) fed a 45%-fat diet with or without an ETWB supplement (20% by wt). Axes represent percentages of the variance that can be accounted for on the basis of cecal microbiota profile. Ellipses represent 95% CIs on the basis of Hotelling's *T*<sup>2</sup> statistic. Each symbol represents 1 mouse. ETWB, enzyme-treated wheat bran.

**TABLE 3** Percent abundance of cecal bacteria phyla and significantly altered taxa in male mice fed a 45%-fat diet with or without an ETWB supplement for 10 wk<sup>1</sup>

	Control	ETWB	Percentage difference (ETWB relative to control) <sup>2</sup>	<i>P</i> <sup>3</sup>
<b>Phylum</b>				
Tenericutes	0.08 ± 0.01	0.20 ± 0.04	150	0.0042
Bacteroidetes	30.8 ± 1.9	43.8 ± 2.7	42	0.0014
Firmicutes	63.6 ± 1.7	53.5 ± 3.0	-16	0.0079
Actinobacteria	1.19 ± 0.40	0.99 ± 0.28	-17	1.00
Verrucomicrobia	4.22 ± 0.54	1.49 ± 0.40	-65	0.0003
Proteobacteria	0.05 ± 0.02	0.01 ± 0.01	-80	0.0015
<b>Taxon<sup>4</sup></b>				
p__Firmicutes; g__ <i>Dorea</i>	0.06 ± 0.01	0.30 ± 0.07	416	0.0008
p__Tenericutes; o__ <i>RF39</i>	0.07 ± 0.01	0.19 ± 0.04	175	0.0056
p__Firmicutes; g__ <i>Adlercreutzia</i>	0.09 ± 0.01	0.18 ± 0.02	99	0.0115
p__Bacteroidetes; f__ <i>Rikenellaceae</i>	4.75 ± 0.43	9.41 ± 0.88	98	0.0010
p__Firmicutes; f__ <i>Ruminococcaceae</i>	3.59 ± 0.62	5.81 ± 0.49	62	0.0057
p__Bacteroidetes; f__ <i>S24-7</i>	26.1 ± 2.0	34.4 ± 2.3	32	0.0392
p__Verrucomicrobia; g__ <i>Akkermansia</i>	4.22 ± 0.54	1.49 ± 0.40	-65	0.0007
p__Firmicutes; c__ <i>Clostridia</i>	4.40 ± 0.47	1.50 ± 0.18	-66	<0.0001
p__Firmicutes; g__ <i>Streptococcus</i>	0.12 ± 0.10	0.04 ± 0.36	-72	<0.0001
p__Firmicutes; g__ <i>Turicibacter</i>	5.91 ± 0.88	1.08 ± 0.27	-82	0.0010
p__Firmicutes; o__ <i>Clostridiales</i>	0.95 ± 0.18	0.08 ± 0.10	-91	<0.0001
p__Firmicutes; f__ <i>Peptostreptococcaceae</i>	0.60 ± 0.17	0.01 ± 0.01	-98	0.0384

<sup>1</sup> Values are means ± SEMs, *n* = 15/group. c., class; ETWB, enzyme-treated wheat bran; f., family; g., genus; o., order; p., phylum.


<sup>2</sup> Percentage difference = [(ETWB - control)/control] × 100.

<sup>3</sup> Group comparisons were assessed by Mann-Whitney *U* tests. *P* values were adjusted for false discovery rate correction. Significance was set at an adjusted *P* value ≤ 0.05.

<sup>4</sup> Reported taxa included had a minimum of 0.05% mean abundance in each group and an adjusted *P* value ≤ 0.05. Bacteria are listed to the lowest level of classification (i.e., if the last taxon assignment is f., “family” is the lowest level of classification).

supplementation led to more robust liver fat combustion, similar to a more “fasted” metabolic state, despite mice being in positive energy balance.

Similarly, several gene expression differences suggest that ETWB shifts liver metabolism toward a fasted phenotype (i.e., increased hepatic β-oxidation and/or reductions in TG



**FIGURE 4** PLS-DA score plots based on abundances of plasma (A) and liver (B) metabolites of male mice fed a 45%-fat diet with or without an ETWB supplement. Ellipses represent 95% CIs on the basis of Hotelling’s *T*<sup>2</sup> statistic; each symbol represents 1 mouse. Annotated metabolites contributing to these plots can be found in Tables 4 and 5; nonannotated metabolites can be found in Supplemental Table 2. Metabolomics analyses were performed on samples from 15 mice/group: a model was developed with the use of 10 mice/group and model validation was performed by using 5 mice/group (Supplemental Figure 1). ETWB, enzyme-treated wheat bran; PLS-DA, partial least-squares-discriminant analysis.

**TABLE 4** Postabsorptive plasma metabolite abundances (ranked highest to lowest by percentage difference) in male mice fed a 45%-fat diet with or without an ETWB supplement for 10 wk<sup>1</sup>

Metabolite <sup>2</sup>	Control	ETWB	Percentage difference (ETWB relative to control) <sup>3</sup>	<i>P</i> <sup>4</sup>		VIP <sup>5</sup>
				MWU	MWU-FDR	
<b>Carbohydrates</b>						
2-Deoxyerythritol	5270 ± 321	7910 ± 444	50	<0.0001	<0.0001	2.12
Ribitol	657 ± 34	835 ± 57	27	0.0240	0.35	1.28
Glucuronic acid	863 ± 36	1060 ± 50	23	0.0030	0.23	1.69
Tagatose	33 ± 3	40 ± 5	19	0.58	0.92	1.42
Fucose + rhamnose	2910 ± 115	3170 ± 109	9	0.09	0.65	1.10
Fructose	6200 ± 818	6690 ± 773	8	0.62	0.92	1.29
Xylitol	284 ± 15	302 ± 15	7	0.33	0.84	1.08
1,5-Anhydroglucitol	13,200 ± 690	9800 ± 343	-26	<0.0001	<0.0001	1.73
<b>Lipids</b>						
β-Sitosterol	294 ± 52	593 ± 80	101	0.0040	0.25	1.32
Pelargonic acid	5280 ± 539	7910 ± 963	50	0.0290	0.35	1.45
Linoleic acid	365 ± 38	537 ± 40	47	0.0070	0.25	1.40
β-Hydroxybutyric acid (3-hydroxybutanoic acid)	13,400 ± 1110	19,600 ± 1950	46	0.0150	0.34	2.02
1-Monostearin	100 ± 11	134 ± 17	34	0.25	0.65	1.48
Capric acid	1070 ± 105	1422 ± 84	33	0.0210	0.35	1.51
Caprylic acid	4419 ± 201	4350 ± 256	-2	0.62	0.92	1.33
<b>Nitrogenous</b>						
γ-Glutamyl-valine	88 ± 9	137 ± 20	56	0.10	0.66	1.52
Cysteine	1680 ± 126	2170 ± 176	29	0.07	0.61	1.31
Methionine sulfoxide	895 ± 54	1060 ± 58	19	0.02	0.35	1.07
Aspartic acid	1710 ± 156	1530 ± 123	-10	0.37	0.84	1.06
2-Hydroxyglutaric acid	1120 ± 48	986 ± 48	-12	0.0290	0.35	1.06
3,6-Dihydro-3,6-dimethyl-2,5-bishydroxypyrazine	564 ± 57	493 ± 45	-13	0.44	0.86	1.18
Creatinine	15,500 ± 1180	13,300 ± 1410	-14	0.33	0.84	1.25
Lactamide minor	407 ± 35	322 ± 19	-21	0.0340	0.38	1.47
Taurine	13,900 ± 1480	10,100 ± 1390	-27	0.0410	0.42	1.16
5-Methoxytryptamine	2840 ± 739	1610 ± 559	-43	0.14	0.70	1.07
Adenosine-5-phosphate	791 ± 272	189 ± 55	-76	0.12	0.70	1.16
<b>Other</b>						
Hydrocinnamic acid (3-phenylproanoic acid)	199 ± 25	403 ± 59	102	0.0010	0.10	1.87
2-Ketoisocaproic acid	2540 ± 174	3160 ± 254	24	0.0330	0.38	1.67
Malonic acid	2660 ± 289	3260 ± 275	22	0.10	0.65	1.05
Benzoic acid	5060 ± 483	6140 ± 291	21	0.07	0.61	1.23
Glyceric acid	2060 ± 140	2390 ± 142	16	0.12	0.69	1.31
Pyruvic acid	16,900 ± 1290	13,000 ± 1230	-23	0.07	0.59	1.58
Lactic acid	355,000 ± 22500	270,000 ± 18400	-24	0.0070	0.25	1.90
Shikimic acid	3470 ± 675	2090 ± 387	-40	0.11	0.67	1.24

<sup>1</sup> Values are means ± SEMs, *n* = 15/group. Only annotated metabolites that had mean bootstrapped VIP measurements ≥1 are presented. Nonannotated metabolites are not shown for the sake of brevity but are provided in Supplemental Table 3. ETWB, enzyme-treated wheat bran; FDR, false discovery rate; MWU, Mann-Whitney *U* test; VIP, variable importance in projection.

<sup>2</sup> Metabolite abundances reported in quantifier ion peak height in the 0.5-μL extract derived from 15 μL plasma.

<sup>3</sup> Percentage difference = [(ETWB - control)/control] × 100.

<sup>4</sup> Group comparisons were assessed by MWUs. *P* values were adjusted for FDR correction. Significance was set at an adjusted *P* value ≤0.05.

<sup>5</sup> VIP was calculated from bootstrapped partial-least-squares discriminant analysis models derived from training data (*n* = 10 mice/group).

synthesis), despite mice being in positive energy balance and gaining weight. Transcriptomics data revealed a reduction in the expression of FA synthase (*Fasn*); a decrease in *Ces3b*, which participates in VLDL assembly (53); and an increase in *Cd36*, which is involved in FA uptake (54) (Supplemental Table 5). In addition, acyl-CoA thioesterase 1 and 3 (*Acot1* and *Acot3*, respectively) were significantly increased in the ETWB group and *Acot4* was also increased. Acot proteins belong to a class of enzymes that cleave thioester bonds of acyl-CoAs, leading to the release of CoA and NEFAs, thus regulating lipid metabolism (55). The expression of several *Acot* genes are upregulated during feed deprivation in mice, including *Acot1*, *Acot3*, and

*Acot4* (56). In addition, the expression of the cytochrome p450 enzymes, *Cyp4a10* and *Cyp4a14*, were significantly increased by ETWB feeding. These enzymes have been shown to increase hepatic lipid oxidation in mice with diet-induced steatohepatitis that lack the main hepatic cytochrome lipid-metabolizing enzyme *Cyp2e1* (57). In addition, mice fed a high-fat diet supplemented with brown rice extract (58) or quercetin (59) displayed increased hepatic gene expression of *Cyp4a10* along with decreased serum and liver TGs and increased levels of genes involved in hepatic lipid metabolism. Hepatic gene expression levels of *Cyp4a10* and *Cyp4a14* in this study correlated with a variety of liver metabolites (Figure 6), including a strong



**TABLE 5** Postabsorptive liver metabolite abundances (ranked highest to lowest by percentage difference) in male mice fed a 45%-fat diet with or without an ETWB supplement for 10 wk<sup>1</sup>

Metabolite <sup>2</sup>	Control	ETWB	Percentage difference (ETWB relative to control) <sup>3</sup>	<i>P</i> <sup>4</sup>		VIP <sup>5</sup>
				MWU	MWU-FDR	
<b>Carbohydrates</b>						
Gluconic acid	521 ± 59	400 ± 67	-23	0.07	0.35	1.35
1,5-Anhydroglucitol	2350 ± 199	1744 ± 95	-26	0.0130	0.19	1.11
Glucose	692,000 ± 29,800	512,000 ± 30,800	-26	0.0000	<0.0001	1.72
Galactonic acid	586 ± 50	421 ± 63	-28	0.0210	0.22	1.73
Xylitol	2440 ± 245	1680 ± 183	-31	0.0410	0.30	1.24
Cellobiotol	104,000 ± 5690	66,000 ± 8290	-37	0.0010	0.0450	1.73
Maltose	404,000 ± 22,100	254,000 ± 33,500	-37	0.0020	0.06	1.72
Ribonic acid	1820 ± 310	1000 ± 227	-45	0.0610	0.35	1.19
Lactobionic acid	25,900 ± 6520	12,400 ± 4710	-52	0.01	0.13	1.52
Ribitol	1490 ± 431	708 ± 232	-53	0.06	0.34	1.20
<b>Lipids</b>						
β-Hydroxybutyric acid (3-hydroxybutanoic acid)	1250 ± 107	1560 ± 1410	25	0.1150	0.43	1.45
5b-Cholesterol	505 ± 39	428 ± 41	-15	0.2130	0.56	1.11
Myristic acid	2610 ± 156	2200 ± 125	-16	0.0670	0.35	1.07
Isoheptadecanoic acid	4640 ± 217	3880 ± 316	-16	0.0620	0.35	1.29
1-Monostearin	623 ± 53	493 ± 37	-21	0.0740	0.35	1.38
Palmitic acid	67,500 ± 4715	52,800 ± 6540	-22	0.0610	0.35	1.11
Oleic acid	18,800 ± 3430	12,700 ± 3340	-33	0.2020	0.55	1.04
Arachidonic acid	17,100 ± 2540	9600 ± 2046	-44	0.0330	0.27	1.17
<b>Nitrogenous</b>						
Aspartic acid	6650 ± 1490	9430 ± 1250	42	0.07	0.35	1.40
2-Aminoadipic acid	464 ± 56	646 ± 57	39	0.0160	0.20	1.51
γ-Glutamyl-valine	186 ± 19	169 ± 17	-9	0.44	0.70	1.08
Alanine	715,000 ± 21,500	629,000 ± 23,300	-12	0.0100	0.17	1.51
Threonine	13,700 ± 1060	11,800 ± 857	-13	0.20	0.55	1.07
Phenylalanine	6320 ± 644	5450 ± 465	-14	0.35	0.65	1.09
Leucine	39,700 ± 3070	33,300 ± 2420	-16	0.15	0.46	1.15
Proline	18,700 ± 1400	15,700 ± 1070	-16	0.12	0.43	1.17
Tyrosine	29,300 ± 2330	23,500 ± 2100	-20	0.09	0.39	1.04
Ornithine	12,300 ± 1180	10,200 ± 1100	-21	0.11	0.42	1.38
Tryptophan	7070 ± 244	5500 ± 242	-22	<0.0001	<0.0001	1.91
Methionine	3530 ± 431	2730 ± 407	-23	0.20	0.55	1.13
Inosine 5'-monophosphate	5670 ± 573	4160 ± 474	-27	0.0450	0.31	1.13
N-acetylmannosamine	617 ± 28	449 ± 31	-27	0.0010	0.05	1.67
Glutamylthreonine	1300 ± 65	937 ± 70	-28	0.0020	0.06	1.65
Nicotinamide	24,600 ± 1665	17,400 ± 1170	-29	0.0020	0.06	1.14
Allantoic acid	2540 ± 314	1690 ± 221	-33	0.0450	0.31	1.12
Xanthine	9110 ± 799	5750 ± 703	-37	0.0070	0.14	1.49
Asparagine	4860 ± 470	3050 ± 291	-37	0.0030	0.08	1.67
Inosine	32,200 ± 2630	19,700 ± 2060	-39	<0.0001	<0.0001	1.43
Hypoxanthine	23,600 ± 3270	13,900 ± 2650	-41	0.0290	0.26	1.13
Uracil	5060 ± 666	2920 ± 404	-42	0.0190	0.22	1.29
Flavin adenine dinucleotide	420 ± 60	239 ± 32	-43	0.0190	0.22	1.26
Cytidine-5'-diphosphate	6350 ± 949	3590 ± 787	-43	0.0190	0.22	1.17
Uridine	2010 ± 334	1100 ± 139	-45	0.0080	0.15	1.63
Glutathione	2200 ± 716	545 ± 107	-75	0.0150	0.20	1.33
<b>Other</b>						
Inositol-4-monophosphate	462 ± 24	424 ± 34	-8	0.27	0.61	1.20
2-Hydroxyglutaric acid	2060 ± 130	1730 ± 165	-16	0.07	0.35	1.16
Pantothenic acid	1100 ± 102	918 ± 124	-17	0.20	0.55	1.34
Idonic acid	1310 ± 70	961 ± 45	-27	<0.0001	<0.0001	1.86
α-Tocopherol	1770 ± 197	1180 ± 100	-33	0.0370	0.29	1.38

<sup>1</sup> Values are means ± SEMs, *n* = 15/group. Only annotated metabolites that had mean bootstrapped VIP measurements ≥1 are presented. Nonannotated metabolites are not shown for the sake of brevity but are provided in Supplemental Table 4. ETWB, enzyme-treated wheat bran; FDR, false discovery rate; MWU, Mann-Whitney *U* test; VIP, variable importance in projection.

<sup>2</sup> Metabolite abundances reported in quantifier ion peak height in the 0.5-μL extract derived from 4 mg liver tissue.

<sup>3</sup> Percentage difference = [(ETWB - control)/control] × 100.

<sup>4</sup> Group comparisons were assessed by MWUs. *P* values were adjusted for FDR correction. Significance was set at an adjusted *P* value ≤0.05.

<sup>5</sup> VIP was calculated from bootstrapped partial least-squares-discriminant analysis models derived from training data (*n* = 10 mice/group).


**TABLE 6** Hepatic gene expression pathways (genes ranked highest to lowest by percentage difference) affected in male mice fed a 45%-fat diet with or without an ETWB supplement for 10 wk<sup>1</sup>

Pathway <sup>2</sup>	Definition	Mean, FPKMs		Percentage difference (ETWB relative to control) <sup>3</sup>
		Control	ETWB	
Metabolic pathways (KEGG pathway 1100) (C = 1184; O = 8; E = 1.15; R = 6.98; rawP = 1.79 × 10 <sup>-5</sup> ; adjP = 0.0002)				
<i>Cyp4a14</i>	Cytochrome P450, family 4, subfamily a, polypeptide 14	284	410	44
<i>Nt5e</i>	5' Nucleotidase, ecto	1.6	2.2	43
<i>Cyp2c37</i>	Cytochrome P450, family 2, subfamily c, polypeptide 37	66.0	86.7	31
<i>Cyp4a10</i>	Cytochrome P450, family 4, subfamily a, polypeptide 10	189	247	31
<i>G6pc</i>	Glucose-6-phosphatase, catalytic	55.1	72.0	31
<i>Hmgcr</i>	3-Hydroxy-3-methylglutaryl-CoA reductase	19.3	14.4	-25
<i>Hyal1</i>	Hyaluronoglucosaminidase 1	13.4	9.6	-28
<i>Alas1</i>	Aminolevulinic acid synthase 1	190	134	-30
Arachidonic acid metabolism (KEGG pathway 590) (C = 90; O = 3; E = 0.09; R = 34.44; rawP = 9.50 × 10 <sup>-5</sup> ; adjP = 0.0006)				
<i>Cyp4a14</i>	Cytochrome P450, family 4, subfamily a, polypeptide 14	284	410	44
<i>Cyp2c37</i>	Cytochrome P450, family 2, subfamily c, polypeptide 37	66.0	86.7	31
<i>Cyp4a10</i>	Cytochrome P450, family 4, subfamily a, polypeptide 10	189	247	31
Biosynthesis of unsaturated FAs (KEGG pathway 1040) (C = 25; O = 2; E = 0.02; R = 82.66; rawP = 0.0003; adjP = 0.0008)				
<i>Acot3</i>	Acyl-CoA thioesterase 3	9.0	12.2	35
<i>Acot1</i>	Acyl-CoA thioesterase 1	19.6	26.4	34
Bile secretion (KEGG pathway 4976) (C = 71; O = 2; E = 0.08; R = 26.29; rawP = 0.0027; adjP = 0.0049)				
<i>Nr0b2</i>	Nuclear receptor subfamily 0, group B, member 2	31.8	45.9	44
<i>Hmgcr</i>	3-Hydroxy-3-methylglutaryl-CoA reductase	19.3	14.4	-25
Retinol metabolism (KEGG pathway 830) (C = 77; O = 4; E = 0.07; R = 53.67; rawP = 1.01 × 10 <sup>-6</sup> ; adjP = 2.02 × 10 <sup>-5</sup> )				
<i>Cyp4a14</i>	Cytochrome P450, family 4, subfamily a, polypeptide 14	284	410	44
<i>Cyp2c37</i>	Cytochrome P450, family 2, subfamily c, polypeptide 37	66.0	86.7	31
<i>Cyp4a10</i>	Cytochrome P450, family 4, subfamily a, polypeptide 10	189	247	31
<i>Cyp26a1</i>	Cytochrome P450, family 26, subfamily a, polypeptide 1	3.7	2.2	-40
Insulin signaling pathway (KEGG pathway 4910) (C = 137; O = 3; E = 0.15; R = 20.44; rawP = 0.0004; adjP = 0.0010)				
<i>Ppp1r3b</i>	Protein phosphatase 1, regulatory (inhibitor) subunit 3B	24.7	33.1	34
<i>Ppp1r3c</i>	Protein phosphatase 1, regulatory (inhibitor) subunit 3C	16.9	22.3	32
<i>G6pc</i>	Glucose-6-phosphatase, catalytic	55.1	72.0	31
Maturity Onset Diabetes of the Young (KEGG pathway 4950) (C = 26; O = 2; E = 0.03; R = 79.48; rawP = 0.0003; adjP = 0.0008)				
<i>Hhex</i>	Hematopoietically expressed homeobox	66.0	42.6	-36
<i>Onecut1</i>	One cut domain, family member 1	10.1	6.3	-38
Vascular smooth muscle contraction (KEGG pathway 4270) (C = 123; O = 3; E = 0.12; R = 25.20; rawP = 0.0002; adjP = 0.0008)				
<i>Cyp4a14</i>	Cytochrome P450, family 4, subfamily a, polypeptide 14	284	410	44
<i>Cyp4a10</i>	Cytochrome P450, family 4, subfamily a, polypeptide 10	189	247	31
<i>Ppp1r12a</i>	Protein phosphatase 1, regulatory (inhibitor) subunit 12A	5.7	3.9	-30
Cell cycle (KEGG pathway 4110) (C = 127; O = 3; E = 0.12; R = 24.41; rawP = 0.0003; adjP = 0.0008)				
<i>Cdkn1a</i>	Cyclin-dependent kinase inhibitor 1A (P21)	1.6	2.5	59
<i>Gadd45g</i>	Growth arrest and DNA-damage-inducible 45γ	11.2	7.9	-29
<i>Myc</i>	Myelocytomatosis oncogene	4.4	2.0	-55
Bladder cancer (KEGG pathway 5219) (C = 43; O = 2; E = 0.04; R = 48.06; rawP = 0.0008; adjP = 0.0018)				
<i>Cdkn1a</i>	Cyclin-dependent kinase inhibitor 1A (P21)	1.6	2.5	59
<i>Myc</i>	Myelocytomatosis oncogene	4.4	2.0	-55

<sup>1</sup> Pathways are derived from liver transcriptomics data. Parameters: Organism: *Mus musculus*, Id Type: gene\_symbol, Reference Set: *mmusculus\_genome*, Statistic: Hypergeometric, Significance Level: Top10, Multiple Test Correction: Benjamini-Hochberg, Minimum number of genes for a category: 2. Genes included have an adjusted *P* value ≤ 0.05. adjP, *P* value adjusted by the multiple test adjustment; ETWB, enzyme-treated wheat bran; FPKM, fragment per kilobase of transcript per million; KEGG, Kyoto Encyclopedia of Genes and Genomes; rawP, *P* value from hypergeometric test.

<sup>2</sup> The C, O, E, and R in parentheses indicate the number of reference genes in the category, number of genes in the gene set and also in the category, the expected number in the category, and the ratio of enrichment, respectively.

<sup>3</sup> Percentage difference = [(ETWB - control)/control] × 100.




**FIGURE 5** Spearman's correlation matrix of metadata, hepatic gene expression, and cecal bacteria compared with PLS-DA–selected plasma metabolites in male mice ( $n = 15/\text{group}$ ) fed a 45%-fat diet with or without an ETWB supplement. Bacteria included had a minimum of 0.05% mean abundance in each group and an adjusted Mann-Whitney  $U$   $P$  value  $\leq 0.05$ . Bacteria are listed to the lowest level of classification (i.e., if the last taxon assignment is f\_, “family” is the lowest level of classification). The direction of ellipses represents positive or negative correlations and the width of ellipses represents the strength of correlation (narrow ellipse = stronger correlation). *Acot*, acyl-CoA thioesterase; *Alas1*, aminolevulinic acid synthase 1; c\_, class; *Cdkn1a*, cyclin-dependent kinase inhibitor 1A; *Cyp*, cytochrome P450; ETWB, enzyme-treated wheat bran; f\_, family; g\_, genus; *Gadd45g*, growth arrest and DNA-damage-inducible 45γ; *G6pc*, glucose-6-phosphatase, catalytic; *Hhex*, hematopoietically expressed homeobox; *Hmgcr*, 3-hydroxy-3-methylglutaryl-CoA reductase; *Hyal1*, hyaluronoglucosaminidase 1; *Myc*, myelocytomatosis oncogene; *Nr0b2*, nuclear receptor subfamily 0, group B, member 2; *Nt5e*, 5' nucleotidase, ecto; o\_, order; *Onecut1*, one cut domain, family member 1; p\_, phylum; PLS-DA, partial least-squares-discriminant analysis; *Ppp1r*, protein phosphatase 1, regulatory (inhibitor); ROS, reactive oxygen species.

negative correlation with glucose. Interestingly, neither *Cyp4a10* nor *Cyp4a14* correlated with liver or plasma concentrations of the ketone body β-hydroxybutyrate; a positive correlation between these variables was thought to have existed on the basis of lipid oxidation increasing ketone body concentrations (60). However, liver ROS did have a significant positive correlation with *Cyp4a14* (Spearman correlation  $r = 0.42$ ,  $P = 0.0351$ ) and a positive but nonsignificant relation with *Cyp4a10* (Spearman correlation  $r = 0.39$ ,  $P = 0.06$ ). Increases in *Cyp4a10* expression have been observed in the small intestine of mice after


being feed-deprived for 24 h (61). Metabolism of hepatic lipids via the cytochrome p450 pathway is of interest not only because it may act to decrease liver lipid accumulation but because it can result in the production of anti-inflammatory arachidonic acid–derived metabolites, such as epoxyeicosanoids.

In addition to alterations in hepatic FA metabolism, there were also marked differences in glucose metabolism in response to ETWB feeding. Glucose concentration was reduced in the livers of ETWB-fed mice, despite plasma glucose concentrations remaining unchanged. Possibly associated with this observation



**FIGURE 6** Spearman's correlation matrix of metadata, hepatic gene expression, and cecal bacteria compared with PLS-DA–selected liver metabolites in male mice ( $n = 15/\text{group}$ ) fed a 45%-fat diet with or without an ETWB supplement. Bacteria are listed to the lowest level of classification (i.e., if the last taxon assignment is f\_, "family" is the lowest level of classification). The direction of ellipses represents positive or negative correlations and the width of ellipses represents the strength of correlation (narrow ellipse = stronger correlation). *Acot1*, acyl-CoA thioesterase; *Alas1*, aminolevulinic acid synthase 1; c\_, class; *Cdkn1a*, cyclin-dependent kinase inhibitor 1A; *Cyp*, cytochrome P450; ETWB, enzyme-treated wheat bran; f\_, family; g\_, genus; *Gadd45g*, growth arrest and DNA-damage-inducible 45γ; *G6pc*, glucose-6-phosphatase, catalytic; *Hhex*, hematopoietically expressed homeobox; *Hmgcr*, 3-hydroxy-3-methylglutaryl-CoA reductase; *Hyal1*, hyaluronoglucosaminidase 1; *Myc*, myelocytomatosis oncogene; *Nr0b2*, nuclear receptor subfamily 0, group B, member 2; *Nt5e*, 5' nucleotidase, ecto; o\_, order; *Onecut1*, one cut domain, family member 1; p\_, phylum; PLS-DA, partial least-squares-discriminant analysis; *Ppp1r*, protein phosphatase 1, regulatory (inhibitor); ROS, reactive oxygen species.





**FIGURE 7** Spearman's correlation matrix of cecal bacteria compared with metadata and hepatic gene expression in male mice ( $n = 15/\text{group}$ ) fed a 45%-fat diet with or without an ETWB supplement. Bacteria included had a minimum of 0.05% mean abundance in each group and an adjusted Mann-Whitney  $U$   $P$  value  $\leq 0.05$ . Bacteria are listed to the lowest level of classification (i.e., if the last taxon assignment is f\_, "family" is the lowest level of classification). The direction of ellipses represents positive or negative correlations and the width of ellipses represents the strength of correlation (narrow ellipse = stronger correlation). *Acot*, acyl-CoA thioesterase; *Alas1*, aminolevulinic acid synthase 1; c\_, class; *Cdkn1a*, cyclin-dependent kinase inhibitor 1A; *Cyp*, cytochrome P450; ETWB, enzyme-treated wheat bran; f\_, family; g\_, genus; *Gadd45g*, growth arrest and DNA-damage-inducible 45y; *G6pc*, glucose-6-phosphatase, catalytic; *Hhex*, hematopoietically expressed homeobox; *Hmgcr*, 3-hydroxy-3-methylglutaryl-CoA reductase; *Hyal1*, hyaluronoglucosaminidase 1; *Myc*, myelocytomatosis oncogene; *Nr0b2*, nuclear receptor subfamily 0, group B, member 2; *Nt5e*, 5' nucleotidase, ecto; o\_, order; *Onecut1*, one cut domain, family member 1; p\_, phylum; PLS-DA, partial least-squares-discriminant analysis; *Ppp1r*, protein phosphatase 1, regulatory (inhibitor); ROS, reactive oxygen species.

was a significant increase in glucose-6-phosphatase mRNA in the livers of ETWB-fed mice. This enzyme, which is typically more active in the fasted state, participates in gluconeogenesis and glycogenolysis and therefore plays an important role in

glucose homeostasis through liver glucose output (62). ETWB-fed mice also showed increased expression of the rate-limiting enzyme for gluconeogenesis, phosphoenolpyruvate carboxykinase 1 (*Pck1*), which is upregulated during fasting (63). However, not all gene expression differences were consistent with a fasted phenotype. The glycogen-targeting regulatory subunits of protein phosphatases, *Ppp1r3b* and *Ppp1r3c*, were increased in the ETWB group; these transcripts have been previously reported to increase in the liver during feeding and to decrease during feed deprivation (64).

The mechanisms by which dietary fiber affects whole-body and hepatic physiology remain to be fully elucidated but are likely driven in part by cecal bacterial populations, which, in turn, could alter specific microbe- and host-derived signaling factors. As expected, ETWB supplementation significantly altered the cecal microbiota. Increases in the Bacteroidetes-to-Firmicutes ratio, as observed in the ETWB-fed mice, have been reported upon feeding high-fiber diets (65) and after weight loss (66). An increase in Bacteroidetes may partially be due to the increased repertoire of carbohydrate-degrading enzymes in the Bacteroidetes phylum (67, 68). The increase in Bacteroidetes was driven by increases in the families *Rikenellaceae* and *S24-7*, which have been reported to increase after high-fiber feeding (69, 70). Decreased abundance of the mucin-degrading bacteria (71) *Akkermansia* in the ETWB group may be of interest because it has been reported to decrease with obesity (72) and appears to have a differential growth response depending on fiber source. *Akkermansia* was reported to increase in aged mice fed resistant starch (73); however, another study found this bacteria to be highest in fiber-free-fed rats compared with rats supplemented with pectin or guar gum (74). A thinning of the host mucin layer concurrent with an increase in *Akkermansia* has been observed when feeding low-carbohydrate diets to mice (75), and this bacteria may therefore play a role in gut barrier function.

Because the liver is the first organ to be bathed in portal blood derived from the gut, we reason that these gut microbe-associated signals will have a profound impact on hepatic (patho)physiology. The most well-established example of gut-derived regulatory factors is the often-observed increase in SCFAs in response to dietary fiber intake. SCFAs serve as fuel or receptor ligands that have been implicated in influencing many processes including the following: gastrointestinal tract growth (76), gut-derived satiety hormones (77), and immune system modulation (78) [also reviewed in (79, 80)]. However, SCFAs are not the sole regulators of host physiology: changes in the gut microbiome lead to alterations in many microbe-derived metabolites, often called "xenobiotics" but more accurately termed "xenometabolites" (81). Indeed, in the current study, there were marked ETWB-related changes in host physiology and liver metabolism that were concurrent with gut microbiome shifts, with no difference in total cecal SCFA abundance, indicating that factors independent of SCFAs were involved. Potential explanations for the lack of change in SCFAs include the following: impairment of microbial fermentation due to the presence of high fat in the diet (82) and increased uptake and utilization by colonic epithelial cells and/or bacteria. Beyond SCFAs, we identified a variety of candidate xenometabolites that are altered by changes in the gut bacteria and that reach the systemic circulation. For example, plasma concentrations of the microbial phenol degradation product 3-phenylpropanoic acid (83, 84) positively correlated with *Rikenellaceae* and negatively correlated with several other cecal bacteria (Figure 5). Microbial degradation of ferulic acid, a purportedly beneficial phenol found in high abundances in wheat bran, has been shown to

increase concentrations of 3-phenylpropanoic acid in vitro (85). Bioaccessibility of ferulic acid by the host is limited and microbial degradation is needed to free this compound in amounts sufficient to increase circulating concentrations (86). *Rikenellaceae* has not previously been reported to play a role in (poly)phenol degradation (87).

Many other significant correlations among cecal bacteria, metabolites, and host phenotype (cecal tissue weight, liver TGs, hepatic genes, and plasma and liver metabolites) were found. However, it remains to be established in future studies which, if any, of the metabolites identified in this report have bioactivities that—directly or indirectly—affect the observed ETWB-associated changes in adiposity, hepatic TG content, lipid and glucose metabolism, and gene regulation. With that said, 5 bacterial taxa that increased with ETWB feeding had negative correlations with adiposity index and liver TGs and a positive correlation with cecal weight (Bacteroidetes families *S24-7* and *Rikellenaceae* and the following Firmicutes order *RF39*, family *Ruminococcaceae*, and genus *Adlercreutzia*). Interestingly, some of these bacterial taxa also correlated with purine metabolites. *Ruminococcaceae* and *RF39* negatively correlated with inosine and hypoxanthine, whereas *Clostridia*, which had a positive correlation with adiposity and liver TGs, also had a positive correlation with inosine and hypoxanthine. Factors produced by these taxa may affect hepatic and whole-body physiology and therefore warrant further study.

ETWB feeding elicited changes in hepatic gene expression related to cell cycle as identified by pathway analysis. The ETWB group showed increased expression of genes reported to be related to cell cycle, such as *Cdkn1a* and *Gdf2*, and a decrease in *Gadd45g*, *Plk3*, and *Myc*. The functional ramifications of these changes are not clear; however, it is perhaps relevant that dietary fiber intake has been associated with decreased incidence of cancer, particularly colon cancer (88–90). In addition to cell cycle, genes involving immune function were also altered by ETWB feeding, such as decreases in *Cish* and *Ikbke*. Interestingly, the consumption of arabinoxylans has been shown to alter innate and adaptive immune function in human and animal models (50). Such observations provide a foundation for hypothesis testing to determine if ETWB and fiber feeding influences hepatic cell cycle and inflammation outcomes.

In conclusion, we have shown that mice that consumed a 45%-fat diet supplemented with 20% ETWB by weight of the diet for 10 wk showed decreased adiposity, lower liver TGs, increased liver ROS, marked differences in plasma and liver metabolites, and changes in hepatic gene expression, including those related to lipid metabolism. It is acknowledged that interpretations related to ETWB effects on the microbiome and metabolome in the current DIO model are confounded by lower weight and adiposity in mice fed this fiber. Thus, future experiments could focus on weight-independent effects of ETWB (i.e., testing parameters at an earlier treatment time point or performing dose-response experiments). Our results help form the foundation for this. If the results in DIO mice are shown in humans, it would support the investigation of ETWB as a potential dietary means to help mitigate or prevent NAFLD and related metabolic disorders. Concurrent with the obesity epidemic, there is an alarming increase in NAFLD in both the adult and pediatric populations and diet is known to greatly affect obesity and related comorbidities (91). Future research should investigate the cellular mechanisms by which specific microbes and xenometabolites associated with ETWB feeding (identified herein) regulate gut, liver, and whole-body systems.

## Acknowledgments

We thank Michael Blackburn and Kikumi Ono-Moore (Arkansas Children's Nutrition Center) for assistance with plasma TG and NEFA measurements as well as Pieter Oort (Western Human Nutrition Research Center) for technical assistance. DAK, SHA, and RJM designed the research and had primary responsibility for the final content; DAK, EBK, MLG, TND, SHA, and RJM conducted the research; MLM, MJK, and KEBK provided essential materials; DAK, BDP, SHA, and RJM analyzed the data; DAK wrote the manuscript; and DAK, BDP, MLM, KEBK, SHA, and RJM edited the manuscript. All authors read and approved the final manuscript.

## References

1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. *Int J Obesity* 2008;32:1431–7.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011;34:274–85.
3. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. *J Pediatr* 2013;162:496–500, e1.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047–53.
5. Pal S, Khossousi A, Binns C, Dhaliwal S, Ellis V. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals. *Br J Nutr* 2011;105:90–100.
6. Babiker R, Merghani TH, Elmusharak K, Badi RM, Lang F, Saeed AM. Effects of gum arabic ingestion on body mass index and body fat percentage in healthy adult females: two-arm randomized, placebo controlled, double-blind trial. *Nutr J* 2012;11:111.
7. Robertson MD, Wright JW, Loizon E, Debard C, Vidal H, Shojae-Moradie F, Russell-Jones D, Umpleby AM. Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndrome. *J Clin Endocrinol Metab* 2012;97:3326–32.
8. Wang J, Cao Y, Wang C, Sun B. Wheat bran xylooligosaccharides improve blood lipid metabolism and antioxidant status in rats fed a high-fat diet. *Carbohydr Polym* 2011;86:1192–7.
9. King DE, Mainous AG III, Lambourne CA. Trends in dietary fiber intake in the United States, 1999–2008. *J Acad Nutr Diet* 2012;112:642–8.
10. USDA. Dietary guidelines for Americans 2010. 7th ed. Washington (DC): USDA; 2010.
11. Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: how prebiotic can work? *Br J Nutr* 2013;109(Suppl 2):S81–5.
12. Graf D, Di Cagno R, Fåk F, Flint HJ, Nyman M, Saarela M, Watzl B. Contribution of diet to the composition of the human gut microbiota. *Microb Ecol Health Dis* 2015;26.
13. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. *Science* 2006;312:1355–9.
14. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010;464(7285):59–65. [cited 2014 Aug 24]. Available from: [http://www.nature.com/nature/journal/v464/n7285/supinfo/nature08821\\_S1.html](http://www.nature.com/nature/journal/v464/n7285/supinfo/nature08821_S1.html).
15. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014;505:559–63.
16. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci USA* 2004;101:15718–23.
17. Keenan MJ, Zhou J, McCutcheon KL, Raggio AM, Bateman HG, Todd E, Jones CK, Tully RT, Melton S, Martin RJ, et al. Effects of resistant starch, a non-digestible fermentable fiber, on reducing body fat. *Obesity (Silver Spring)* 2006;14:1523–34.

18. Jensen MT, Cox RP, Jensen BB. Microbial production of skatole in the hind gut of pigs given different diets and its relation to skatole deposition in backfat. *Anim Sci* 1995;61:293–304.
19. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. *Gut* 2013;62:1787–94.
20. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proc Natl Acad Sci USA* 2009;106:3698–703.
21. Ingerslev AK, Theil PK, Hedemann MS, Laerke HN, Bach Knudsen KE. Resistant starch and arabinoxylan augment SCFA absorption, but affect postprandial glucose and insulin responses differently. *Br J Nutr* 2014;111:1564–76.
22. Thomas AP, Dunn TN, Oort PJ, Grino M, Adams SH. Inflammatory phenotyping identifies CD11d as a gene markedly induced in white adipose tissue in obese rodents and women. *J Nutr* 2011;141:1172–80.
23. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 1957;226:497–509.
24. Ali SF, LeBel CP, Bondy SC. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. *Neurotoxicology* 1992;13:637–48.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265–75.
26. Barry KA, Wojcicki BJ, Bauer LL, Middelbos IS, Vester Boler BM, Swanson KS, Fahey GC. Adaptation of healthy adult cats to select dietary fibers in vivo affects gas and short-chain fatty acid production from fiber fermentation in vitro. *J Anim Sci* 2011;89:3163–9.
27. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc Natl Acad Sci USA* 2011;108(Suppl 1):4516–22.
28. Yin X, Yan Y, Kim EB, Lee B, Marco ML. Short communication: effect of milk and milk containing *Lactobacillus casei* on the intestinal microbiota of mice. *J Dairy Sci* 2014;97:2049–55.
29. Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, Mills DA, Caporaso JG. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. *Nat Methods* 2013;10:57–9.
30. Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics* 2011;27:2957–63.
31. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl Environ Microbiol* 2006;72:5069–72.
32. Fiehn O, Kind T. Metabolite profiling in blood plasma. *Methods Mol Biol* 2007;358:3–17.
33. Fiehn O, Wohlgemuth G, Scholz M. Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. In: Ludäscher B, Raschid L, editors. *Data integration in the life sciences*. Berlin, Heidelberg (Germany): Springer; 2005. p. 224–39.
34. Scholz M, Fiehn O. SetupX—a public study design database for metabolomic projects. Stanford (CA): Shriram Center for BioE & ChemE. *Pac Symp Biocomput* 2007:169–80.
35. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. *Nucleic Acids Res* 2005;33(Web Server issue):W741–8.
36. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GENE SeT AnaLysis Toolkit (WebGestalt): update 2013. *Nucleic Acids Res* 2013;41(Web Server issue):W77–83.
37. Oort PJ, Warden CH, Baumann TK, Knotts TA, Adams SH. Characterization of Tusc5, an adipocyte gene co-expressed in peripheral neurons. *Mol Cell Endocrinol* 2007;276:24–35.
38. R Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2014.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* 1995;57:289–300.
40. Mevik B, Wehrens R., Liland, KH. PIs: partial least squares and principal component regression. *J Stat Software*; 2013.
41. Komsta L. Outliers: tests for outliers. R package version 0.14. [Internet]; 2011 [cited 2014 Aug 8]. Available from: <http://CRAN.R-project.org/package=outliers>.
42. Wong J. Imputation: imputation. R package version 2.0.1 [Internet]. [cited 2014 Aug 8]. Available from: <http://CRAN.R-project.org/package=imputation>.
43. Mehmood T, Liland KH, Snipen L, Sæbø S. A review of variable selection methods in partial least squares regression. *Chemom Intell Lab Syst* 2012;118:62–9.
44. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. *Chemom Intell Lab Syst* 2001;58:109–30.
45. Canty A, Ripley B. Boot: Bootstrap R (S-Plus) functions. R package version 2.0.1. [Internet]; 2015 [cited 2015 Sep 15]. Available from: <https://cran.r-project.org/package=boot>.
46. Neyrinck AM, Van Hee VF, Piront N, De Backer F, Toussaint O, Cani PD, Delzenne NM. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. *Nutr Diabetes* 2012;2:e28.
47. Neyrinck AM, Possemiers S, Druart C, Van de Wiele T, De Backer F, Cani PD, Larondelle Y, Delzenne NM. Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. *PLoS One* 2011;6:e20944.
48. Lu ZX, Walker KZ, Muir JG, O’Dea K. Arabinoxylan fibre improves metabolic control in people with Type II diabetes. *Eur J Clin Nutr* 2004;58:621–8.
49. Broekaert WF, Courtin CM, Verbeke K, Van de Wiele T, Verstraete W, Delcour JA. Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. *Crit Rev Food Sci Nutr* 2011;51:178–94.
50. Zhang S, Li W, Smith CJ, Musa H. Cereal-derived arabinoxylans as biological response modifiers: extraction, molecular features, and immunostimulating properties. *Crit Rev Food Sci Nutr* 2015;55:1035–52.
51. Kristensen M, Jensen MG, Aarestrup J, Petersen K, Søndergaard L, Mikkelsen MS, Astrup A. Flaxseed dietary fibers lower cholesterol and increase fecal fat excretion, but magnitude of effect depend on food type. *Nutr Metab (Lond)* 2012;9.
52. Reddy JK, Mannaerts GP. Peroxisomal lipid metabolism. *Annu Rev Nutr* 1994;14:343–70.
53. Lian J, Wei E, Wang SP, Quiroga AD, Li L, Di Pardo A, van der Veen J, Spione S, Mitchell GA, Lehner R. Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis in mice. *Hepatology* 2012;56:2154–62.
54. Xu S, Jay A, Brunaldi K, Huang N, Hamilton JA. CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane. *Biochemistry* 2013;52:7254–61.
55. Hunt MC, Alexson SEH. The role acyl-CoA thioesterases play in mediating intracellular lipid metabolism. *Prog Lipid Res* 2002;41:99–130.
56. Ellis JM, Bowman CE, Wolfgang MJ. Metabolic and tissue-specific regulation of acyl-CoA metabolism. *PLoS One* 2015;10.
57. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. *J Clin Invest* 2000;105:1067–75.
58. Jang H-H, Park M-Y, Kim H-W, Lee Y-M, Hwang K-A, Park J-H, Park D-S, Kwon O. Black rice (*Oryza sativa* L.) extract attenuates hepatic steatosis in C57BL/6 J mice fed a high-fat diet via fatty acid oxidation. *Nutr Metab (Lond)* 2012;9:27.
59. Hoek-van den Hil EF, Keijer J, Bunschoten A, Vervoort JJ, Stankova B, Bekkenkamp M, Herreman L, Venema D, Hollman PC, Tvrzicka E, et al. Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in mice. *PLoS One* 2013;8:e51588.
60. Cahill GF. Fuel metabolism in starvation. *Annu Rev Nutr* 2006;26:1–22.
61. van den Bosch HM, Bunger M, de Groot P, van der Meijde J, Hooiveld G, Muller M. Gene expression of transporters and phase III metabolic enzymes in murine small intestine during fasting. *BMC Genomics* 2007;8:267.
62. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. *Annu Rev Nutr* 1999;19:379–406.
63. She P, Shiota M, Shelton KD, Chalkley R, Postic C, Magnuson MA. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. *Mol Cell Biol* 2000;20:6508–17.

64. Luo X, Zhang Y, Ruan X, Jiang X, Zhu L, Wang X, Ding Q, Liu W, Pan Y, Wang Z, et al. Fasting-induced protein phosphatase 1 regulatory subunit contributes to postprandial blood glucose homeostasis via regulation of hepatic glycogenesis. *Diabetes* 2011;60:1435–45.
65. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci USA* 2010;107:14691–6.
66. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006;444(7122):1022–3. [cited 2014 Sep 18]. Available from: [http://www.nature.com/nature/journal/v444/n7122/supinfo/4441022a\\_S1.html](http://www.nature.com/nature/journal/v444/n7122/supinfo/4441022a_S1.html).
67. Kaoutari AE, Armougom F, Gordon JI, Raoult D, Henrissat B. The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. *Nat Rev Micro* 2013;11(7):497–504. [cited 2014 Sep 18]. Available from: <http://www.nature.com/nrmicro/journal/v11/n7/abs/nrmicro3050.html#supplementary-information>.
68. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. *Nat Rev Microbiol* 2012;10:323–35.
69. Lee SM, Han HW, Yim SY. Beneficial effects of soy milk and fiber on high cholesterol diet-induced alteration of gut microbiota and inflammatory gene expression in rats. *Food Funct* 2015;6:492–500.
70. Zhong Y, Nyman M, Fak F. Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt. *Mol Nutr Food Res* 2015;59:2066–76.
71. Derrien M, Vaughan EE, Plugge CM, de Vos WM. *Akkermansia muciniphila* gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. *Int J Syst Evol Microbiol* 2004;54:1469–76.
72. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, et al. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci USA* 2013;110:9066–71.
73. Tachon S, Zhou J, Keenan M, Martin R, Marco ML. The intestinal microbiota in aged mice is modulated by dietary resistant starch and correlated with improvements in host responses. *FEMS Microbiol Ecol* 2013;83:299–309.
74. Jakobsdottir G, Xu J, Molin G, Ahrné S, Nyman M. High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. *PLoS One* 2013;8:e80476.
75. Earle KA, Billings G, Sigal M, Lichtman JS, Hansson GC, Elias JE, Amieva MR, Huang KC, Sonnenburg JL. Quantitative imaging of gut microbiota spatial organization. *Cell Host Microbe* 2015;18:478–88.
76. Sakata T. Stimulatory effect of short-chain fatty acids on epithelial cell proliferation in the rat intestine: a possible explanation for trophic effects of fermentable fibre, gut microbes and luminal trophic factors. *Br J Nutr* 1987;58:95–103.
77. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, Keenan MJ. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. *Am J Physiol Endocrinol Metab* 2008;295:E1160–6.
78. Arpaia N, Campbell C, Fan X, Dikly S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffey PJ, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013;504:451–5.
79. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. In: Frederick WA, editor. *Adv Immunol* 2014;121:91–119.
80. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat Rev Endocrinol* 2015;11:577–91.
81. Campbell C, Grapov D, Fiehn O, Chandler CJ, Burnett DJ, Souza EC, Casazza GA, Gustafson MB, Keim NL, Newman JW. Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut origin. *PLoS One* 2014;9:e84260.
82. Charrier JA, Martin RJ, McCutcheon KL, Raggio AM, Goldsmith F, Goita M, Senevirathne RN, Brown IL, Pelkman C, Zhou J, et al. High fat diet partially attenuates fermentation responses in rats fed resistant starch from high-amylose maize. *Obesity (Silver Spring)* 2013;21:2350–5.
83. Selma MV, Espín JC, Tomás-Barberán FA. Interaction between phenolics and gut microbiota: role in human health. *J Agric Food Chem* 2009;57:6485–501.
84. Ou K, Sarnoski P, Schneider KR, Song K, Khoo C, Gu L. Microbial catabolism of procyanidins by human gut microbiota. *Mol Nutr Food Res* 2014;58:2196–205.
85. Anson NM, Selinheimo E, Havenaar R, Aura AM, Mattila I, Lehtinen P, Bast A, Poutanen K, Haenen GR. Bioprocessing of wheat bran improves in vitro bioaccessibility and colonic metabolism of phenolic compounds. *J Agric Food Chem* 2009;57:6148–55.
86. Zhao Z, Egashira Y, Sanada H. Digestion and absorption of ferulic acid sugar esters in rat gastrointestinal tract. *J Agric Food Chem* 2003;51:5534–9.
87. Duda-Chodak A, Tarko T, Satora P, Sroka P. Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review. *Eur J Nutr* 2015;54:325–41.
88. Bradbury KE, Appleby PN, Key TJ. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Clin Nutr* 2014;100(Suppl 1):394S–8S.
89. Aune D, Chan DSM, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. *BMJ* 2011;343.
90. Zhang Z, Xu G, Ma M, Yang J, Liu X. Dietary fiber intake reduces risk for gastric cancer: a meta-analysis. *Gastroenterology* 2013;145:113–20, e3.
91. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006;118:1388–93.